Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-04-28
2009-12-29
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07638511
ABSTRACT:
Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.
REFERENCES:
patent: 4626536 (1986-12-01), Pfirrmann
patent: 5416091 (1995-05-01), King
patent: 5593665 (1997-01-01), Pfirrmann et al.
patent: 6080397 (2000-06-01), Pfirrmann
patent: 6521616 (2003-02-01), Calabresi et al.
patent: 2302720 (2000-09-01), None
patent: 0 253 662 (1988-01-01), None
patent: 1066830 (2001-01-01), None
patent: WO 91/13628 (1991-09-01), None
patent: WO 92/00743 (1992-01-01), None
Dimmock et al, “Mannich bases of phenolic azobenzenes possessing cytotoxic activity”, Eur. J. Med. Chem., vol. 32, pp. 583-594 (1997).
Bedrosian, I. et al., “Taurolidine, an Analogue of the Amino Acid Taurine, Suppresses Interleukin-1 and Tumor Necrosis Factor Synthesis in Human Peripheral Blood Mononuclear Cells”, Cytokine 3(6): 568-575, 1991.
Clarke, K. et al., KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma,J Clin OncolAug. 1999; 17(8) 2579-84.
Jacobi, C.A. et al., Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model,Am J of Surgery,174, Sept. 1997, 359-363.
Jacobi, C.A. et al., Intraperitoneal installation of taurolidine and heparin for the prevention of intraperitoneal tumor growth and trocar metastases in laparoscopic surgery in a rat model,Langenbecks Arch Chir(1997) 382 [Suppl 1]: S31-S36.
Monson, J.R.T. et al., Abrogation of tumor necrosis factor (TNF) toxicity in the murine model by taurolidine: support for synergism of TNF with endotoxin,Br. J. Surg.,77(6), Jun. 1990, A708.
Monson, J.R.T. et al., Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial,Br. J. Surg.,77(6), Jun. 1990, A711.
Monson, J.R.T. et al., Taurolidine as an anti-neoplastic agent: a previously undiscovered role?,Br. J. Surg.,77(12), Dec. 1990, 1432.
Monson, J.R.T., et al., Taurolidine inhibits tumour necrosis factor (TNF) toxicity—new evidence of TNF and endotoxin synergy,Euro. J. Surg. Oncology1993; 19:226-231.
Japanese Office Action entitled “Preliminary Notice of Reasons for Rejection”, Dec. 4, 2008, and English language translation, pp. 1-7.
Pfirrmann Rolf W.
Stendel Ruediger
ED. Geistlich Sohne AG fur Chemische Industrie
Krass Frederick
Packard Benjamin
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Methods and compositions for treating primary and secondary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating primary and secondary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating primary and secondary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081371